Meridian Bioscience Inc. (NASDAQ:VIVO) is set to announce third quarter earning results on Friday 7th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, VIVO to report 3Q20 income of $ 0.23 per share from revenue of $ 66.04 million.
For the full year, analysts anticipate top line of $ 235.58 million, while looking forward to income of $ 0.75 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 230.00 million ~ $ 236.00 million, where as bottomline are predicted in a range of $ 0.70 ~ $ 0.75 per share
Click Here For More Historical Outlooks Of Meridian Bioscience Inc.
Previous Quarter Performance
Meridian Bioscience Inc. disclosed income for the second quarter of $ 0.23 per share, from the revenue of $ 57.30 million. The quarterly earnings hiked 21.05 percent compared with the same quarter last year. Street analysts expected Meridian Bioscience Inc. to report income of $ 0.08 per share on revenue of $ 49.26 million for the second quarter. The bottom line results beat street analysts by $ 0.15 or 187.50 percent, at the same time, top line results outshined analysts by $ 8.04 million or 16.32 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Meridian Bioscience Inc.
Stock Performance
The company has a market capital of $ 1.02 billion and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”VIVO” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Meridian Bioscience Inc. will be hosting a conference call at 10:00 AM eastern time on 7th August 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.meridianbioscience.com
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT!
